The following Structured Product Label (SPL) was submitted to the FDA by Medical Products Laboratories, Inc. for the product Lumicain (NDC 10733-412). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding dosage & administration, warnings and precautions, package label.principal display panel, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
FOR TOPICAL APPLICATION ONLY
For Granulation Tissue Growth: Allow packing saturated in Lumicain to remain in nail groove for 48 hours; repeat if necessary.
If hemmorrhage is profuse, dress wound with gauze saturated with Lumicain and allow to remain for 24 hours or longer.
CAUTION: Federal Law restricts sale and use to physician or licensed practitioner.
premier lumicainTM Topical Hemostatic Solution 60cc
For Rapid Control of Minor Hemorrhage
Each Gram Contains: Aluminium Chloride............250 mg.
In an aqueous base.Enter section text here
* Please review the disclaimer below.
